# Breaking the PRRSV-2 Life Cycle in Porcine Alveolar Macrophages: Tylvalosin’s Multi-Stage Inhibition

## TL;DR

Tylvalosin can inhibit PRRSV replication in pig lung cells by targeting multiple stages of the virus's life cycle, offering a potential new tool for controlling PRRS.

## Contribution

Tylvalosin's multi-stage inhibition of PRRSV in porcine alveolar macrophages is newly demonstrated.

## Key findings

- Tylvalosin inhibits replication of both NADC30-like and NADC34-like PRRSV strains in a dose-dependent manner.
- Tylvalosin blocks multiple stages of the PRRSV life cycle, particularly for the NADC34-like strain.
- Tylvalosin shows antiviral activity when co-incubated with the virus or administered post-infection.

## Abstract

Porcine reproductive and respiratory syndrome (PRRS) remains a significant threat to the global swine industry, with no fully effective control measures currently available. This study explored the efficacy of tylvalosin against PRRSV and its potential mechanisms of action. The findings indicated that tylvalosin effectively inhibited the replication of both NADC30-like and NADC34-like strains of PRRSV in porcine alveolar macrophages (PAMs), with the inhibitory effect increasing as the concentration of tylvalosin rose. Interestingly, pre-treatment with tylvalosin did not significantly impact the replication of the NADC30-like strain but did suppress the NADC34-like strain. However, when tylvalosin was co-incubated with the viruses or administered post-infection, it successfully inhibited PRRSV replication. Further investigation revealed that tylvalosin could interfere with multiple stages of the PRRSV life cycle. Specifically, it demonstrated antiviral activity against all four stages of the NADC34-like strain’s infectious cycle but did not affect the adsorption phase of the NADC30-like strain. Overall, these results highlight tylvalosin’s ability to suppress PRRSV infection in PAMs by targeting various stages of the viral life cycle. This research not only contributes to the clinical management of PRRS but also provides a foundation for future studies on the antiviral potential of tylvalosin against PRRSV.

Porcine reproductive and respiratory syndrome (PRRS) is one of the most serious diseases threatening the swine industry worldwide. However, no satisfactory control strategy has existed until now. In this study, the effectiveness of tylvalosin against PRRSV and the underlying mechanism was investigated. The results showed that in porcine alveolar macrophages (PAMs), tylvalosin can inhibit the replication of the NADC30-like and NADC34-like strains in a dose-dependent manner. It is worth noting that pre-incubation with tylvalosin had no significant inhibitory effect on the NADC30-like strain but did inhibit the NADC34-like strain. Co-incubation of both viruses and tylvalosin or post-incubation with tylvalosin after viral infection inhibited PRRSV. We further analyzed the effect of tylvalosin on different stages of PRRSV replication and found that the stages in the PRRSV life cycle could be blocked by tylvalosin. Tylvalosin has an antiviral effect on all four stages of the NADC34-like strain’s infectious cycle but has no effect against the adsorption phase of the NADC30-like strain. These results demonstrated that tylvalosin suppressed PRRSV infection in PAMs and inhibited PRRSV infection at multiple steps of the viral life cycle. This study will contribute to the clinical prevention and control of PRRS and provide a basis for further exploration of the anti-PRRSV effects of tylvalosin.